Related Experiment Videos
Randomized, controlled evaluation of a prototype informed consent process for HIV vaccine efficacy trials
Anne S Coletti1, Patrick Heagerty, Amy R Sheon
1Family Health International, Research Triangle Park, North Carolina, USA.
Journal of Acquired Immune Deficiency Syndromes (1999)
|February 7, 2003
Summary
A new informed consent process significantly improved understanding of HIV vaccine trial concepts among high-risk individuals. This enhanced knowledge was sustained and consistent across diverse demographic groups.
Area of Science:
- Clinical Trials
- Infectious Disease Research
- Public Health
Background:
- Ensuring valid informed consent is crucial for ethical HIV vaccine efficacy trials.
- Participant understanding of complex trial concepts can be a significant barrier.
Purpose of the Study:
- To evaluate a prototype informed consent process for HIV vaccine efficacy trials.
- To assess the impact of the process on participant knowledge and willingness to enroll.
Main Methods:
- A prospective cohort study (HIV Network for Prevention Trials Vaccine Preparedness Study) involving 4,892 high-risk individuals.
- A randomly selected subset (20%) underwent a prototype informed consent process at 3 months.
- Knowledge and willingness to participate were assessed at baseline and semi-annually for 18 months.
Main Results:
- Baseline knowledge of HIV vaccine trial concepts was generally low.
- Participation in the prototype process led to significant and sustained increases in knowledge (RR 1.04-2.26).
- Knowledge gains were consistent across various HIV risk, racial/ethnic, and educational groups.
Conclusions:
- The prototype informed consent process effectively enhances participant understanding of HIV vaccine trials.
- This process is recommended for adoption in future HIV vaccine efficacy trials and other clinical research.
- The findings support the use of structured informed consent to improve trial participation and ethical conduct.